Robert Davis on revenue guidance
From MRK Stock | Merck & Co. Inc. Q1 2026 Earnings Call · · AlphaStreet
“We're confident that this change will best position us to deliver on a potential commercial opportunity of over 70 billion by the mid 2030s from these 20 plus anticipated new growth drivers alone.”
On , Robert Davis, Chairman, President & Chief Executive Officer at Merck & Co Inc, spoke about revenue guidance during MRK Stock | Merck & Co. Inc. Q1 2026 Earnings Call on AlphaStreet.
About Robert Davis
Robert Davis, chairman and chief executive officer of Merck, discussed the company's commercial and pipeline strategy during recent earnings calls. He stated that Merck is in the midst of launching over 20 new products, which he described as having blockbuster potential, and announced an evolution of the company's commercial operating structure into a business unit model organized around products and therapeutic areas. Davis said the company is confident this change will position it to deliver on a potential commercial opportunity of over $70 billion by the mid-2030s. He noted that the company continues to focus on business development, prioritizing deals in the $1 to $15 billion range, but has the capacity to go beyond that for the right strategic deal. Davis also said the company does not see a need for a large, synergy-driven transformative acquisition, as it has a robust pipeline. Davis highlighted several pipeline developments, including the expectation of first-time phase three data readouts in 2026 for islatravir combined with lenacapavir as a potential once-weekly oral HIV regimen, MK-3000 for retinal diseases, and tolisokibart for ulcerative colitis. He also discussed a multi-year partnership with Google Cloud to scale AI capabilities, a collaboration with Tempest AI for precision oncology, and an agreement with the Mayo Clinic to leverage clinical and genomic data. Davis stated that Merck is making significant investments in U.S. manufacturing, including a groundbreaking at its Elkton, Virginia site as part of a broader plan to invest more than $70 billion in domestic manufacturing and R&D. Regarding U.S. healthcare policy, Davis said the company shares the administration's goal of decreasing patient out-of-pocket costs while seeking greater prices for its products in countries that he said have not been paying fair value.